Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Patient Information Leaflet last updated on the eMC: 20/12/2011
PIL AREDIA Dry Powder 15mg, 30mg and 90mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 20/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 05/12/2011 and displayed until 20/12/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 15/09/2010 and displayed until 05/12/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 16/09/2009 and displayed until 15/09/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 03/04/2008 and displayed until 16/09/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 22/04/2005 and displayed until 03/04/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 18/03/2005 and displayed until 22/04/2005
Reasons for adding or updating:
  • Change to side-effects
Updated on 07/05/2004 and displayed until 18/03/2005
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 20/08/2002 and displayed until 07/05/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 02/01/2001 and displayed until 20/08/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   pamidronate disodium